Active ingredient: Choline alfoscerate
Dosage form: oral solution
There are contraindications. Read the drug label and check with your physician before use.
Gliatilin (Choline alfoscerate) belongs to the group of central cholinomimetics with a predominant effect on the central nervous system. Choline alfoscerate has a positive effect on memory function and cognitive ability, as well as on indicators of emotional state and behavior, deterioration of which was caused by involutional processes in the brain. It plays an important role in post-stroke rehabilitation and therapy for conditions such as cerebrovascular insufficiency, dyscirculatory encephalopathy.
A unique form of the oral solution is suitable for all the patients, regardless of their condition. However, for weakened patients, with difficulty of swallowing, and disorders of conduct is the frontline therapy.
Convenient reception – therapeutic daily dose (1200 mg) is reached in 2 administrations.
It is made from original substances – phosphate. It ensures maximum penetration of choline through the blood-brain barrier.
Russian multicenter and international studies show excellent results on the background of treatment with Gliatilin on rehabilitation of patients after stroke, head injury, with cerebrovascular diseases, cognitive disorders of various origins.
Gliatilin, unlike citicoline, has a dual mechanism of action, delivers greater amounts of choline in the brain, so its effect persists even after termination of course of treatment.
This section of the site contains specialized professional information. In accordance with Federal Law of the Russian Federation No. 38-FZ “On Advertising” dated March 13, 2006, the information in this section is intended exclusively for medical and pharmaceutical workers.
Are you a medical/pharmaceutical professional?
WHERE TO BUY
Italfarmaco, founded in 1938, stands out vividly on the background of the leading Italian pharmaceutical manufacturers with the innovative portfolio certified according to GMP and FDA standards. More than 2.2 thousand employees of Italfarmaco SpA provide the highest quality of customer service in Italy, Russia, Switzerland, Spain, Portugal, Greece, Turkey, Chile, Peru, Morocco, the USA and Brazil. In 2015, the company EFFIK International became a part of the group of companies of Italfarmaco SpA. Activities of Italfarmaco SpA with the headquarters in Milan aimed at solving significant social challenges in the cardiovascular, immuno-oncological, gynecological, dermatological, orthopedic and neurological areas of medicine. The Russian division of Italfarmaco exists since 1999 and has focused on promoting gynecological and endocrinology portfolio of Italfarmaco SpA for women’s health, assisted reproductive technologies and solutions to the problems of osteoporosis. Innovative products, ethical business and professional team characterizes the Russian division of Italfarmaco.